Glisoxepide (INN) is an orally available anti-diabetic drug from the group of sulfonylureas.[1] It belongs to second-generation sulfonylureas.[2]
Names | |
---|---|
Preferred IUPAC name
N-[2-(4-{[(Azepan-1-yl)carbamoyl]sulfamoyl}phenyl)ethyl]-5-methyl-1,2-oxazole-3-carboxamide | |
Identifiers | |
| |
3D model (JSmol)
|
|
ChEMBL |
|
ChemSpider |
|
DrugBank |
|
ECHA InfoCard | 100.042.329 |
KEGG |
|
PubChem CID
|
|
UNII |
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C20H27N5O5S | |
Molar mass | 449.52388 g/mol |
Pharmacology | |
A10BB11 (WHO) | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
verify (what is ?)
Infobox references
|